Department of Pharmacology and Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt.
Diabetes Metab Res Rev. 2019 Jul;35(5):e3130. doi: 10.1002/dmrr.3130. Epub 2019 Apr 8.
Dysregulation of miRNAs has been associated with many clinical conditions, including coronary artery disease (CAD). MiRNAs roles in patients with type 2 diabetes mellitus (T2D) with or without CAD, however, have not been clearly understood. Therefore we studied the expression of miRNAs 342 and 450 and the activity of the NADPH oxidase 4 (NOX-4), and their association with anthropometric and biochemical parameters of hyperglycaemia and dyslipidaemia.
Blood was collected from 200 outpatient subjects, divided into four groups of 50 individuals including control, T2D, CAD, and T2D with CAD. CAD was further divided based on CAD with angina, CAD clots, and CAD ischaemia to differentiate the primary cause of CAD. We measured the miRNAs 342 and 450 expression and NOX-4 activity, in addition to routine parameters.
The expression of miRNAs 342 and 450 and NOX-4 activity was significantly different between groups. Furthermore, they presented significant correlations with routine parameters, providing evidence of a potentially beneficial role in stratifying the risk for CAD in patients with T2D.
The results of this study suggest that the expression of miRNAs 342 and 450 and NOX-4 activity may help identify those individuals with T2D at high risk for developing CAD as well as the prognosis in those with established CAD.
miRNA 的失调与许多临床情况有关,包括冠状动脉疾病 (CAD)。然而,miRNA 在 2 型糖尿病 (T2D) 患者伴或不伴 CAD 中的作用尚未被明确理解。因此,我们研究了 miRNA 342 和 450 的表达以及 NADPH 氧化酶 4 (NOX-4) 的活性,及其与高血糖和血脂异常的人体测量和生化参数的相关性。
从 200 名门诊患者中采集血液,将其分为四组,每组 50 人,包括对照组、T2D 组、CAD 组和 T2D 合并 CAD 组。根据 CAD 是否伴有心绞痛、CAD 血栓形成和 CAD 缺血进一步对 CAD 进行分组,以区分 CAD 的主要病因。我们测量了 miRNA 342 和 450 的表达和 NOX-4 活性,以及常规参数。
miRNA 342 和 450 的表达和 NOX-4 活性在各组之间有显著差异。此外,它们与常规参数呈显著相关,为 T2D 患者 CAD 风险分层提供了潜在有益作用的证据。
这项研究的结果表明,miRNA 342 和 450 的表达和 NOX-4 活性可能有助于识别 T2D 患者中发生 CAD 风险较高的个体,以及已确诊 CAD 患者的预后。